Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 4 | 5 |
1.1 List of Tables | 6 | 1 |
1.2 List of Figures | 7 | 2 |
2 Introduction | 9 | 13 |
2.1 Disease Introduction | 9 | 1 |
2.2 Epidemiology | 9 | 1 |
2.3 Symptoms | 10 | 2 |
2.4 Etiology | 12 | 1 |
2.5 Pathophysiology | 12 | 1 |
2.6 Disease Stages | 13 | 1 |
2.7 Diagnosis | 14 | 3 |
2.8 Prognosis | 17 | 1 |
2.9 Treatment | 18 | 1 |
2.9.1 Treatment Algorithm | 18 | 2 |
2.9.2 Mild-to-Moderate AD | 20 | 1 |
2.9.3 Moderate-to-Severe AD | 21 | 1 |
3 Marketed Products | 22 | 3 |
3.1 Aricept (donepezil) Eisai | 22 | 1 |
3.2 Exelon (rivastigimine) Novartis | 22 | 1 |
3.3 Razadyne (galanatamine) Janssen | 23 | 1 |
3.4 Namenda/Ebixa/Axura/Abixa (memantine), Merz Pharma/Lundbeck/Forest/Daiichi Sankyo | 23 | 1 |
3.5 Cognex (tacrine) Shiniogi | 24 | 1 |
3.6 Namzaric (memantine ER + donepezil), Actavis-Adamas | 24 | 1 |
4 Heat Map Marketed Products Overview | 25 | 1 |
5 Pipeline Product Developments | 26 | 24 |
5.1 The Pipeline Development Landscape | 26 | 1 |
5.2 Mechanisms of Action in the Pipeline | 27 | 4 |
5.3 Clinical Trials | 31 | 1 |
5.3.1 Failure Rate | 31 | 1 |
5.3.2 Clinical Trial Duration | 32 | 2 |
5.3.3 Clinical Trial Size | 34 | 4 |
5.3.4 Competitive Clinical Trials Metric Analysis | 38 | 1 |
5.4 Promising Pipeline Molecules | 39 | 1 |
5.4.1 MK-8931 Merck &Co. | 39 | 1 |
5.4.2 LMTX (methylthioninium chloride) TauRX Therapeutics | 40 | 1 |
5.4.3 AZD3293 AstraZeneca | 41 | 1 |
5.4.4 AB1010 AB Science | 42 | 1 |
5.4.5 BIIB037 Biogen | 43 | 1 |
5.4.6 TP488 vTv Therapeutics | 44 | 1 |
5.4.7 EVP-6124 FORUM Pharmaceuticals | 45 | 1 |
5.4.8 LuAE58054 Lundbeck | 46 | 1 |
5.4.9 Gantenerumab (R-1540/RG-1450) Roche | 47 | 3 |
6 Heat Map Pipeline Products Overview | 50 | 1 |
7 Market Forecast to 2021 | 51 | 23 |
7.1 Geographical Markets | 51 | 1 |
7.1.1 Global Market | 51 | 4 |
7.1.2 North America | 55 | 1 |
7.1.2.1 Treatment Usage Patterns | 55 | 3 |
7.1.2.2 Annual Cost of Treatment | 58 | 1 |
7.1.2.3 Market Size | 59 | 2 |
7.1.3 European Union Five | 61 | 1 |
7.1.3.1 Treatment Usage Patterns | 61 | 2 |
7.1.3.2 Annual Cost of Treatment | 63 | 2 |
7.1.3.3 Market Size | 65 | 3 |
7.1.4 Japan | 68 | 1 |
7.1.4.1 Treatment Usage Patterns | 68 | 2 |
7.1.4.2 Annual Cost of Treatment | 70 | 2 |
7.1.4.3 Market Size | 72 | 2 |
8 Drivers and Barriers | 74 | 2 |
8.1 Drivers | 74 | 1 |
8.1.1 Rising Prevalence | 74 | 1 |
8.1.2 Increasing Public and Policy-Maker Awareness | 74 | 1 |
8.1.3 Innovation in Pipeline | 74 | 1 |
8.1.4 Growing Understanding of AD Pathophysiology | 74 | 1 |
8.2 Barriers | 74 | 1 |
8.2.1 Sales Erosion by Generics | 74 | 1 |
8.2.2 High Clinical Failure RatesAD has a particularly high clinical trial failure rate. | 75 | 1 |
8.2.3 Drug Testing in Patients with Established AD and Advanced Neurodegeneration | 75 | 1 |
8.2.4 Low Diagnosis and Treatment Rate | 75 | 1 |
9 Strategic Consolidations | 76 | 11 |
9.1 Licensing Deals | 76 | 4 |
9.1.1 Cephalon Enters into Licensing Agreement with Mesoblast | 80 | 1 |
9.1.2 Lundbeck Enters into Licensing Agreement with Otsuka | 80 | 1 |
9.1.3 Roche Enters into Licensing Agreement with Prothera | 80 | 1 |
9.1.4 GlaxoSmithKline Enters into Licensing Agreement with AFFiRiS | 81 | 1 |
9.2 Major Co-development Deals | 81 | 4 |
9.2.1 Lundbeck Enters into Co-development Agreement with Otsuka | 85 | 1 |
9.2.2 GlaxoSmithKline Enters into Agreement with EPIX Pharma | 85 | 1 |
9.2.3 Evotec Enters into Co-development Agreement with Roche | 86 | 1 |
9.2.4 Pfizer Enters into Co-development Agreement with Medivation | 86 | 1 |
10 Appendix | 87 | 58 |
10.1 All Pipeline Drugs by Phase | 87 | 46 |
10.1.1 Discovery | 87 | 9 |
10.1.2 Preclinical | 96 | 20 |
10.1.3 Phase I | 116 | 3 |
10.1.4 Phase II | 119 | 3 |
10.1.5 Phase III | 122 | 2 |
10.1.6 Market Forecasts to 2021 | 124 | 1 |
10.1.6.1 Global | 124 | 1 |
10.1.6.2 US | 125 | 1 |
10.1.6.3 Canada | 126 | 1 |
10.1.6.4 UK | 127 | 1 |
10.1.6.5 France | 128 | 1 |
10.1.6.6 Germany | 129 | 1 |
10.1.6.7 Italy | 130 | 1 |
10.1.6.8 Spain | 131 | 1 |
10.1.6.9 Japan | 132 | 1 |
10.2 Bibliography | 133 | 6 |
10.3 Abbreviations | 139 | 1 |
10.4 Research Methodology | 140 | 5 |
10.4.1 Secondary Research | 141 | 1 |
10.4.2 Marketed Product Profiles | 141 | 1 |
10.4.3 Late-Stage Pipeline Candidates | 141 | 1 |
10.4.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products | 141 | 1 |
10.4.5 Product Competitiveness Framework | 142 | 1 |
10.4.6 Pipeline Analysis | 142 | 1 |
10.4.6.1 Overall Pipeline | 142 | 1 |
10.4.6.2 Clinical Trials | 142 | 1 |
10.4.6.2.1 Failure Rate | 142 | 1 |
10.4.6.2.2 Clinical Trial Size | 142 | 1 |
10.4.6.2.3 Clinical Trial Duration | 143 | 1 |
10.4.6.2.4 Clinical trial Endpoint Analysis | 143 | 1 |
10.4.7 Forecasting Model | 143 | 1 |
10.4.8 Deals Data Analysis | 144 | 1 |
10.5 Contact Us | 144 | 1 |
10.6 Disclaimer | 144 | 1 |